X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ABSK021 (pimicotinib) is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor. It is being evaluated in phase 3 studies for the treatment of inoperable tenosynovial giant cell tumor (TGCT).
Lead Product(s): Pimicotinib
Therapeutic Area: Oncology Product Name: ABSK021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
ABSK021 (pimicotinib) is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor. It is being evaluated for for the treatment of tenosynovial giant cell tumor (TGCT).
Lead Product(s): Pimicotinib
Therapeutic Area: Oncology Product Name: ABSK021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
Under the agreement, Merck will receive an exclusive license to commercialize ABSK021 (pimicotinib), an oral, highly selective and potent small-molecule antagonist of colony stimulating factor-1 receptor, currently in Phase III for tenosynovial giant cell tumor.
Lead Product(s): Pimicotinib
Therapeutic Area: Oncology Product Name: ABSK021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Undisclosed Upfront Cash: $70.0 million
Deal Type: Licensing Agreement December 04, 2023
Details:
The licensed small-molecule antagonist of EGFR ABK3376 is a pre-clinical candidate developed by Abbisko Therapeutics' proprietary drug discovery platform, which is a novel, highly potent, selective, and brain-penetrating new-generation EGFR inhibitor.
Lead Product(s): ABK3376,Furmonertinib
Therapeutic Area: Oncology Product Name: ABK3376
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Shanghai Allist Pharmaceuticals
Deal Size: $187.9 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 01, 2023
Details:
Under the terms of the Agreement, Abbisko Therapeutics will be responsible for the further discovery and development of molecules that modulate a novel and challenging drug target using its proprietary R&D platform.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $258.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
